Sonoma Pharmaceuticals Inc. [SNOA] Revenue clocked in at $12.12 million, up 2.00% YTD: What’s Next?

Sonoma Pharmaceuticals Inc. [NASDAQ: SNOA] gained 2.74% or 0.0 points to close at $0.18 with a heavy trading volume of 13612762 shares. The company report on January 9, 2024 at 9:15 AM that NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network.

NovaBay Pharmaceuticals, Inc. (NYSE American:NBY) and Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union. The new products will combine Sonoma’s existing eye product Ocudox®, which has already received a Class IIB CE mark for sale in the European Union, with Avenova branding, and are expected to be marketed through Sonoma’s established European distribution network. This agreement brings together NovaBay’s deep knowledge of eye care reflected in its Avenova brand with Sonoma’s expertise in distributing hypochlorous acid products overseas.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Sonoma will manufacture Ocudox by Avenova with packaging similar to NovaBay’s Avenova products, which are the leading hypochlorous acid-based eye care products in the U.S. Sonoma will pay NovaBay a royalty fee based on net product sales of Ocudox by Avenova, and Sonoma will continue to market its Ocudox product in the European Union.

It opened the trading session at $0.183, the shares rose to $0.2263 and dropped to $0.1744, the range by which the price of stock traded the whole day. The daily chart for SNOA points out that the company has recorded -82.96% loss over the past six months. However, it is still -50.0% lower than its most recent low trading price.

If we look at the average trading volume of 1.06M shares, SNOA reached to a volume of 13612762 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Sonoma Pharmaceuticals Inc. [SNOA]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNOA shares is $3.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNOA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for Sonoma Pharmaceuticals Inc. is set at 0.03, with the Price to Sales ratio for SNOA stock in the period of the last 12 months amounting to 0.21. The Price to Book ratio for the last quarter was 0.17, with the Price to Cash per share for the same quarter was set at 0.16.

Trading performance analysis for SNOA stock

Sonoma Pharmaceuticals Inc. [SNOA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.10. With this latest performance, SNOA shares dropped by -6.74% in over the last four-week period, additionally sinking by -82.96% over the last 6 months – not to mention a drop of -83.86% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNOA stock in for the last two-week period is set at 47.75, with the RSI for the last a single of trading hit 52.65, and the three-weeks RSI is set at 42.19 for Sonoma Pharmaceuticals Inc. [SNOA]. The present Moving Average for the last 50 days of trading for this stock 0.1735, while it was recorded at 0.1839 for the last single week of trading, and 0.7630 for the last 200 days.

Sonoma Pharmaceuticals Inc. [SNOA]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Sonoma Pharmaceuticals Inc. [SNOA] shares currently have an operating margin of -34.43 and a Gross Margin at +33.73. Sonoma Pharmaceuticals Inc.’s Net Margin is presently recorded at -38.81.

Return on Total Capital for SNOA is now -48.39, given the latest momentum, and Return on Invested Capital for the company is -60.09. Return on Equity for this stock declined to -61.78, with Return on Assets sitting at -28.94. When it comes to the capital structure of this company, Sonoma Pharmaceuticals Inc. [SNOA] has a Total Debt to Total Equity ratio set at 10.64. Additionally, SNOA Total Debt to Total Capital is recorded at 9.62, with Total Debt to Total Assets ending up at 5.17. Long-Term Debt to Equity for the company is recorded at 2.03, with the Long-Term Debt to Total Capital now at 1.84.

Reflecting on the efficiency of the workforce at the company, Sonoma Pharmaceuticals Inc. [SNOA] managed to generate an average of -$30,123 per employee. Receivables Turnover for the company is 5.33 with a Total Asset Turnover recorded at a value of 0.75.Sonoma Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 3.48.

An analysis of Institutional ownership at Sonoma Pharmaceuticals Inc. [SNOA]

The top three institutional holders of SNOA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in SNOA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in SNOA stock with ownership which is approximately 5.8325%.